CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma

about

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma

Item

http://www.wikidata.org/entity/Q37301779

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CRKL mediates EML4-ALK signali ...... rearranged lung adenocarcinoma

@en

CRKL mediates EML4-ALK signali ...... earranged lung adenocarcinoma.

@nl

type

Item

label

CRKL mediates EML4-ALK signali ...... rearranged lung adenocarcinoma

@en

CRKL mediates EML4-ALK signali ...... earranged lung adenocarcinoma.

@nl

prefLabel

CRKL mediates EML4-ALK signali ...... rearranged lung adenocarcinoma

@en

CRKL mediates EML4-ALK signali ...... earranged lung adenocarcinoma.

@nl

P1476

CRKL mediates EML4-ALK signali ...... rearranged lung adenocarcinoma

@en

P2093

Arjan Gower

http://www.w3.org/2001/XMLSchema#string

Donna Voeller

http://www.w3.org/2001/XMLSchema#string

Rong An

http://www.w3.org/2001/XMLSchema#string

Yisong Wang

http://www.w3.org/2001/XMLSchema#string

Yu-Wen Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

The biology and treatment of EML4-ALK non-small cell lung cancer

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

P304

29199-29210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8638

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

In-Kyu Kim

P577

2016-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

300088049

http://www.w3.org/2001/XMLSchema#string

P698

27078848

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5045389

http://www.w3.org/2001/XMLSchema#string